Anticipating What's Around the Bend

Icon_Sun.svg The Road to BIO: Day 6

Tuesday, June 13, 2017
Georgia /// Mississippi
Featured Sponsor: UPM Pharmaceuticals
James E. Gregory, President & CEO of UPM Pharmaceuticals, discusses the benefits of being a family-owned CDMO in terms of flexibility and transparency. Watch the full interview.

Ed Scholtz, Ph.D., Vice President of R&D, UPM Pharmaceuticals, shares how UPM’s rich history as an R&D company helps inform of potential gaps early on in the development process. Watch the full interview.

Driving Molecules to Market

UPM’s seven-acre Bristol, TN headquarters houses over 450,000 square feet of commercial-scale manufacturing space, which means we have the capacity to handle these types of molecules, regardless of volume or scale. Leveraging dedicated facility space and equipment, we were able to develop and bring to market the only two oral peptides currently on the market. 

Flexibility in Service

Because we are a private, family-owned business, we can make decisions rapidly, and without having to go through a corporate bureaucracy. This flexibility affords us the ability to take onboard clients with various situations, and to facilitate the development of the products they believe in.

Advancing Formulation Development Efforts

UPM has a rich history as an R&D company. Our experience enables us to anticipate what we think our customers may need, and to identify gaps based on just preliminary discussion. UPM has worked with every type of company—from virtual to big pharma—and has a proven track record of adapting to the requirements of both to optimize their chances of success. 

Promoting Transparency Through Effective Project Management

At UPM, your project manager is your on-site advocate as well as your scientist. Our goal is to function with complete transparency, so we employ an instant communication system, updating our clients as their projects progress. Because the owners of UPM have been on both sides of the fence, both as a finished product pharma company and now a CDMO, they have an in-depth understanding of what is needed and will never call a client with a problem without offering solutions. 

Limiting Future Manufacturing Constraints

UPM bought into a facility with great capacity to create flexibility and options for clients. We have significant warehouse space to store raw materials, and have plenty of room for expansion to meet clients’ needs. UPM specializes in small molecule, oral solid dose and semi solid products, low humidity suites, and has significant infrastructure for controlled drug substance manufacturing and storage as well as scalability from concept to commercialization for tablets, capsules and semi-solid products.


About UPM Pharmaceuticals

UPM is an independent CDMO offering formulation development, cGMP manufacturing, analytical methods development and stability testing from concept to commercialization. UPM specializes in dosages with oral routes of administration, in solid dosage forms such as capsules and tablets, and semi-solid creams and ointments. We offer customized services to clients of all sizes and employ quality management systems characteristic of a customer-focused business. 


James E. Gregory

James E. Gregory has served as the President and Chief Operating Officer of UPM from 2004 until the present. Gregory previously worked for King Pharmaceuticals from 1995 to 2000 as Executive Vice President and General Manager of King’s Bristol, Tennessee manufacturing facility. He served in various consulting capacities at King from 2000 to 2003 and served on the Board of Directors in 2002 and 2003. Gregory served from 1982 to 1995 as a senior administrator in the court systems of Phoenix, Arizona and Washington, D.C. He was deputy executive officer in charge of business operations of the District of Columbia Court System from 1990 to 1995. Gregory has a B. A. from the University of Maryland and a Masters in Public Administration from American University.